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Financing  innovative  medical  devices  is  an  important  challenge  for national  health  pol-
icy  makers,  and  a  crucial  issue  for hospitals.  However,  when  innovative  medical  devices
are launched  on  the  European  market  there  is  generally  little  clinical  evidence  regarding
both  efﬁcacy  and  safety,  both  because  of  the  ﬂaws  in the  European  system  for regulating
such  devices,  and because  they are  at an early  stage  of development.  To manage  the  uncer-
tainty surrounding  the  reimbursement  of innovation,  several  European  countries  have  set
up  temporary  funding  schemes  to  generate  evidence  about  the  effectiveness  of devices.  This
article explores  two  different  French  approaches  to funding  innovative  in-hospital  devices
and collecting  supplementary  data: the  coverage  with  evidence  development  (CED)  scheme
introduced  under  Article  L. 165-1-1  of  the  French  Social  Security  Code;  and  national  pro-
grams  for  hospital-based  research.  We  discuss  pros  and  cons  of  both  approaches  in the  light
of  CED  policies  in Germany  and  the UK. The  CED  policies  for devices  share  common  limi-
tations.  Thus,  transparency  of  CED  processes  should  be enhanced  and  decisions  need  to  be
made in a timely  way.  Finally,  we  think  that  closer  collaboration  between  manufacturers,
health  authorities  and  hospitals  is essential  to make  CED policies  more  operational.
©  2014  Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC BY-NC-ND  license. IntroductionIn 2009, the market for medical devices in France was
 19 billion, with between 800,000 and 2 million marketed
roducts [1]. The French National Health Insurance (NHI)
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repaid D 8.3 billion (43%) [1]. The rest was borne by pri-
vate insurers and patients and consisted mainly of medical
aids such as hearing aids, glasses or dentures. Most medical
devices for individual use in French hospitals are covered by
a diagnosis-related group (DRG)-based payment. However,
hospitals can be reluctant to use new and costly technolo-
gies until the DRG-based payment system is updated to
account for their additional costs [2,3]. Thus, to facilitate
the adoption of innovative health technologies by hospi-
tals, most European countries using a DRG-based payment
system have established additional payment instruments
[2].
In France, additional payments for in-hospital devices
reached D 1.5 billion in 2009 [1]. In contrast, additional
 BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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payments for expensive hospital drugs reached D 2.5 bil-
lion at the same time. Additional payment for in-hospital
devices is only applicable to implantable devices and
to those included on the list of products and services
qualifying for reimbursement (LPPR). Applications for
reimbursement are made solely by manufacturers and not
by the institutional users (hospitals) [4]. For innovative
devices and for devices that do not match any existing
deﬁnition on the LPPR, a dossier is submitted by the man-
ufacturer to the National Committee of Medical Devices
and Health Technologies (CNEDIMTS) for assessment [5].
To be included on the LPPR, there must be clinical data
demonstrating the expected clinical beneﬁt of the device,
including the efﬁcacy/safety ratio, and also showing that
it is superior to existing technologies or alternative treat-
ments [4,5].
However, for most medical devices arriving on the EU
market, there is little efﬁcacy evidence available and even
less evidence about cost-effectiveness [6]. This is mainly
due to deﬁciencies in the EU regulations and particu-
larly the vagueness of EU Directives on medical devices
about requirements for premarketing trials (Directives
90/385/EEC, 93/42/EEC and 98/8/EC updated and amended
by Directive 2007/47/EC) [6–8]. In addition, short prod-
uct life cycles, methodological difﬁculties for designing
trials (particularly for randomization and blinding) and
managing the operator’s learning curve, do not encour-
age manufacturers to set up long-term studies to generate
evidence [9–11]. To manage the uncertainty surrounding
the reimbursement of innovative devices, health author-
ities in European countries, and particularly Germany,
UK and France propose temporary reimbursement, com-
monly called coverage with evidence development (CED)
schemes, and simultaneously collect clinical effectiveness
and/or cost effectiveness data [12,13]. Apart from reim-
bursement schemes, special funding for national research
projects may  also be made available to collect evidence
within a given period of time for innovative medical
devices; this is the case in France and in the UK [14,15].
Using the viewpoint of the hospital, we assess these
two different approaches to temporary funding for inno-
vative devices, both of which are currently implemented
in France. We  then consider the pros and cons of both
approaches and compare the French CED scheme to com-
parable schemes used in two other European countries:
Germany which has very recently introduced a CED
scheme, and the UK where this type of scheme has been
operational for many years [16,17]. Finally, we  discuss
potential improvements for CED policies applied to devices
in these three European countries.
2. Special funding schemes for innovative medical
devices in French hospitals
2.1. The CED approach from Article L. 165-1-1
Generally, the aim of CED schemes is to provide provi-
sional access to new medical products while collecting the
evidence needed to determine whether deﬁnitive cover-
age is warranted [18]. This method differs from traditional
postmarketing evidence generation in that the objective oflth Policy 117 (2014) 1–5
the supplementary evidence collection is to reduce uncer-
tainty around a speciﬁc aspect of the evidence base [19].
Thus, the value of CED is that it allows healthcare decision
makers to make available a medical product in a controlled
manner while also deﬁning what evidence is required to
support further diffusion of the technology [20].
Article L. 165-1-1 of the French Social Security Code
has set rules, established in 2009 and applicable since
March 2010, of conditional coverage for innovative health
products, services or interventions [21]. This has been
developed for promising health products for which the
CNEDIMTS is not able to establish the clinical beneﬁt due
to insufﬁcient data. Only the CNEDIMTS can select eligi-
ble products and does so on the basis of technological
intelligence or applications for LPPR reimbursement. Thus,
manufacturers cannot apply for the CED scheme. The opin-
ion issued is submitted to the French Ministry of Health for
a decision; the Ministry establishes a decree indicating the
number of patients to be involved, the speciﬁc conditions of
use, the funding period and the list of hospitals leading the
study. The French Ministry of Health has to specify require-
ments for studies, but the law is unclear on this point and
clinical and/or cost effectiveness studies may  be involved.
Finally, a temporary fee including intervention, hospital-
ization and product costs is granted for two years by the
NHI [14]. Currently, only very few devices have been des-
ignated as eligible by the CNEDIMTS and a single decision
from the French Ministry of Health has been taken very
recently.
2.2. Programs for hospital-based research
The French Ministry of Health also provides grants to
hospital-based research programs to promote innovation
within hospitals. After annual national and regional calls
for proposals, lump sums are delivered to cover a limited
period; this is funded by an envelope dedicated to public
interest missions. Research teams in university hospitals
identify candidate health technologies and submit projects
in response to the relevant national or regional calls for
tender [22]. Projects are reviewed and ranked by indepen-
dent experts in accordance with French priorities for public
health. Among ﬁve programs, only two  are relevant to inno-
vative medical devices: the Program for Hospital Clinical
Research (PHRC) and the Program for Medical Economic
Research (PRME).
The purpose of the PHRC is to promote the transfer of
drugs or devices at an early stage of development from
fundamental research to clinical research [23]. Projects are
designed as clinical research trials for demonstrating safety
and efﬁcacy and have to conform to the national research
priorities established by the French Ministry of Health. In
2012, 112 PHRC projects were funded nationally: nine (8%)
concerned devices and together received a total funding of
D 3.9 million [24].
Unlike the PHRC, PRME projects do not involve devices
at a pre-marketing stage, but only CE-marked devices
[23]. PRME projects have to focus on cost-effectiveness
analysis and should expressly provide an incremental
cost-effectiveness ratio (ICER). In 2011, six PRME projects
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edicated to devices were funded by the French Ministry
f Health for a total amount of D 5.5 million [25].
. Pros and cons of the two different approaches
.1. Pros
The French CED permits the early involvement of health
uthorities which establish guidance for reducing uncer-
ainty in view of national reimbursement. This point is
ecisive because, at the end of the temporary coverage, a
ecision has to be taken in a timely way to avoid a gap in the
unding for the technology which could be ﬁnancially detri-
ental for hospitals [26]. Another advantage of the French
ED involve the ﬁnancial arrangements: full coverage is
ffered, not requiring any refunds by the manufacturer.
his approach is economically attractive to the manufac-
urer, because collecting supplementary evidence does not
nvolve making a loss [13].
PHRC/PRME programs confer on hospitals the job of
dentifying promising innovations and thereby ensure
esponsiveness and better acceptability by end-users [27].
hese programs are in great demand by hospitals. For
xample, there were 582 PHRC projects for drugs and
evices submitted in 2012 [24]. Clearly, they help French
ospitals undertaking studies on speciﬁc medical devices
nd can be used for, in particular, costly and non-
mplantable devices not covered by additional payments.
urthermore, they increase the clinical data available, and
specially data speciﬁc to the French context [14].
.2. Cons
Both approaches provide funding for a limited period.
n the context of PHRC/PRME programs, hospitals some-
imes have to ﬁnd supplementary funding for longer-term
rojects or, worse, stop the project before the programmed
nd [1]. With the French CED, manufacturers receive ﬁnan-
ial support for two years, but the law does not specify what
appens at the end of this period.
Only the CNEDIMTS is empowered to determine
hether a device meets the criteria of the French CED [21].
o ofﬁcial deﬁnition of an innovative product or inter-
ention is available and this is consequently left to the
nterpretation of the committee. Furthermore, the leading
rench medical device industry association indicates that
he process for innovations is much too slow [28]. Indeed,
hree health technologies were selected by the CNEDIMTS
n December 2011 with no further decision taken. Very
ecently, and to everyone’s surprise, the French Ministry
f Health gave its approval for a retinal prosthesis sys-
em which had not even been selected among the three
echnologies in 2011.
By providing data speciﬁc to the French context,
HRC/PRME studies are, in theory, upstream from CNED-
MTS evaluations for additional payment. Consequently,
he French Ministry of Health recently decided that the
NEDIMTS should undertake no evaluation of a device
ndergoing PHRC/PRME studies [29]. Thus, implementing
 PHRC/PRME study may  paradoxically introduce delay in
NEDIMTS evaluation and the ﬁnal reimbursement processlth Policy 117 (2014) 1–5 3
[14]. In addition, these programs are not an option of the
national reimbursement scheme. As a result, there is no
guarantee that the device, even if the data collected are suf-
ﬁcient, will ultimately be reimbursed. Finally, PHRC/PRME
programs run by hospital-based teams can in some cases
be redundant with the international clinical research pro-
grams run by the manufacturer [14].
4. Comparison to other European countries
The three European countries with the largest expendi-
tures on medical devices – Germany, France and the UK –
have all applied CED to innovative procedures and devices
[3,14,16,17]. The main features of these CED schemes are
presented in Table 1.
In Germany, a law of the German Social Code in 2012
(Section 137e SGB V) introduced a CED scheme run by
the Federal Joint Committee (G-BA) [17,30]. Under this
scheme, the manufacturer applies for assessment by the
G-BA; note that this is impossible with the French CED
scheme [31]. Then, if the procedure is deemed to have
“potential” after evaluation by the G-BA and if a device is
involved, health authorities offer a partial ﬁnancial sup-
port, up to 50%, to the manufacturer for evaluations [17,31].
It is important to note that the German CED focuses on
new diagnostic and therapeutic treatment methods rather
than on the device itself. The company is also obliged to
refund the G-BA once the device is ﬁnally reimbursed. By
contrast, as we describe above, French health authorities
provide a full ﬁnancial support with no refunds required.
However, the French CED only concerns one manufacturer
at a time, whereas the German system makes it possi-
ble for more than one manufacturer with similar devices
to become involved in the trial [17,31]. Since 1999, the
National Institute for Health and Clinical Excellence (NICE)
may  recommend the use of a health technology (drugs,
procedures or devices) in the context of evidence develop-
ment [16]. Two  different recommendations for collecting
evidence can be issued: “Only In Research” (OIR) for which
the technology is used solely for patients participating in
a research program; or “Approval With Research” (AWR)
for which the health technology can be used routinely
with further research needed. In contrast to the German
and French policies, the funding process is not formally
described by the NICE [32]. Indeed, research can be funded
by the manufacturer or the public sector, for instance
the National Institute for Health Research (NIHR) and the
National Health Service (NHS). Like the French and German
health authorities, NICE speciﬁes the nature of the evidence
required, but not clearly how studies should be designed
[32].
OIR/AWR recommendations, like the French CED, are
perceived by manufacturers as an additional delay in mak-
ing innovations generally available [16,28]. Since 2006,
NICE has proposed a faster process which makes possible
issuing guidance closer to the time of marketing autho-
rization [33]. This process, called the “single technology
appraisal” (STA) process, was designed to appraise a sin-
gle health product with a single indication [34]. OIR/AWR
recommendations can be used within the STA process.
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Table 1
Main features of CED schemes in Germany, France and the UK.
Country France Germany UK
CED scheme Article 165-1-1 Section 137e SGB V OIR/AWR
Year established 2009 2012 1999
Actors involved CNEDIMTS, French
Ministry of Health
G-BA, IQWiG NICE, NIHR
Health technologies Procedures and devices Procedures and devices† Procedure, devices and drugs
Financial support Full coverage Partial coverage (50%
maximum–70% for rare diseases)
No standard
Funding period 2 years No standard No standard
Refund by the manufacturer No Yes Manufacturers or NIHR fund the trial
Number of manufacturers involved Only one One or more Only one
Number of decisions for procedures/devices 1 Unpublished data 13*
AWR: Approval With Research; CNEDIMTS: National Committee of Medical Devices and Health Technologies; G-BA: Federal Joint Committee; IQWiG:
Institute for Quality and Efﬁciency in Healthcare; NIHR: National Institute for Health Research; NICE: National Institute for Health and Clinical Excellence;
han on tOIR:  Only In Research.
* Between 2000 and 2010 [16].
† Focus on new diagnostic and therapeutic treatment methods rather t
However, it seems that the use of OIR/AWR recommen-
dations has dramatically declined since the introduction of
the STA process [16].
5. Discussion and policy implications
Most European countries using a DRG-based payment
system have introduced additional reimbursement com-
ponents to facilitate the adoption of innovative medical
devices in hospitals [2,3]. In France, many in-hospital
devices for individual use do not fulﬁl the requirements
for additional payments; this is particularly true for
many costly and innovative non-implantable devices or
implantable devices for which only little evidence is avail-
able. For such devices, the CED scheme and PHRC/PRME
programs can help to narrow the gap and to fund stud-
ies for collecting evidence. In the light of the experience of
three large European countries, as described in Section 4,
it appears that CED schemes still require improvements to
make them more operational.
Indeed, the transparency of CED processes should
be enhanced, in particular by clearly stating the selec-
tion criteria for devices that may  beneﬁt from such
approaches [14,31,32]. Also, CED decisions need to be made
more quickly [28,32]. This point has already been high-
lighted before and lessons could be learned from what
has been done by NICE with the STA process [20,34].
If CED schemes were no longer to be perceived as a
supplementary barrier, it would contribute to improve col-
laboration between manufacturers, health authorities and
also hospitals. Indeed, effective collaboration between all
stakeholders is undoubtedly the cornerstone of success for
the CED approach [35]. From the viewpoint of the hospital,
PHRC/PRME programs work well because physicians are
involved early in the process. As a result, projects are more
likely to be successfully established, because they corre-
spond to the hospitals’ expectations in accordance with
local needs. Therefore, French health authorities are cur-
rently considering cooperation networks with university
hospitals to strengthen evidence collection [1]. Finally, trial
funding seems to be a key issue for CED policies. In France,
funding in both schemes is for a limited period whereas,
[he device itself.
in the UK, research budgets are not clearly designated by
NICE. This has to be modiﬁed, especially for the many small
companies in the medical device sector which do not neces-
sarily have sufﬁcient resources to conduct long-term trials
[36]. This is a particularly important point, because manu-
facturers have no assurance that the device will ultimately
be reimbursed. Thus, the German approach which involves
the manufacturer refunding the ﬁnancial support once the
innovative device is reimbursable could also be exploited
in, or adapted to, other countries [31].
In conclusion, CED schemes for innovative medical
devices offer great potential for collecting evidence and
reducing uncertainty. However, transparency, timeliness,
closer collaboration between all stakeholders and pre-
dictability for manufacturers are key challenges that need
to be addressed in order to make CED policies more effec-
tive.
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